Development and Optimization of Candesartan Cilexetil Loaded Solid Lipid Nanoparticles

Introduction: SLNs have a surfactant-stabilized solid lipid core. They circumvent liquid lipid constraints and increase drug stability. Lipids promote oral medication absorption through the lymphatic pathway and replace hepatic first-pass metabolism. Using a 2-factor, 3-level, 32 full factorial design, the researchers optimized percentage Encapsulation Efficiency (%EE), drug content, and particle size to enhance the candesartan cilexetil-loaded SLN formulation. Materials and Methods: The BCS class II low soluble Candesartan was used to formed as SLN and optimized utilizing independent variables Imwitor 900K and tween 60 concentrations and dependent factors %EE, drug content, and particle size. FTIR showed no drug-excipient interaction. Along with in vitro drug release. Results: The optimized 13 formulations had %EE from 78.47 to 94.61, drug concentration from 57 to 107%, and particle size from 357 to 705 nm. SEM showed that certain particles were coagulated and near-spherical, supporting particle size and dispersion. C-SLN-7 released 60.39% and C-SLN-12 46.4% during 24 hr in vitro. BCS class II low soluble CC's calibration curve was a straight line with an R2 value of 0.9978, indicating the drug's standard curve. The improved SLN formulation may improve oral bioavailability of poorly soluble medicines. Conclusion: The enhanced SLN formulation of candesartan cilexetil increased encapsulation efficiency, drug content, particle size, and in vitro drug release. Changes in lymphatic absorption may improve oral absorption of highly lipophilic medicines. The work sheds light on SLNs' lipophilic drug delivery potential.